title: [Perfluorocarbonic compounds application as a new approach in pathogenic treatment of severe forms of viral hepatitis].
abstract: Perfluorocarbonic blood substitute Perftoran (PF) was used in combined intensive therapy of 79 patients with severe viral hepatitis B as a polyfunctional pathogenetic drug according to the following scheme: intravenously 400 ml 1-2 times a day for 2-6 days (800-2400 ml per course). PF exhibited immunomodulating, antioxidant, membrane-stabilizing and disintoxicating properties. The immunomodulating effect of the drug manifested itself in its influence on functional activity of macrophages, reduction of their oversection of proinflammatory cytokines: IL-1 beta, IL-6, IL-8, TNF-alpha. Antioxidant properties were established on the basis of the ability of PF to lower activity of prooxidant factors (myeloperoxidase of neutrophilic granulocytes) and to stimulate antioxidant factors (catalase, glucose-6-phosphatedehydrogenase), reduced glutathione in erythrocytes). As a membranostabilizer, PF increased resistance of erythrocyte membranes to peroxide hemolysis and improved their rheological indices (deformability and viscosity). A disintoxication effect of PF led to reduction of middle-molecular peptides content in plasma. PF had a noticeable effect on basic clinicobiochemical indices in patients with a severe course of viral hepatitis B as well as the disease course and outcomes. Finally, PF reduced the duration of treatment of patients with severe viral hepatitis B in hospital and intensive care units. It is inferred that administration of infusion drugs on the basis of perfluorocarbonic compounds holds promise in pathogenetic therapy of viral hepatitides.
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Kovelenov
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Lobzin
mesh_terms: D005260:Female; D005466:Fluorocarbons / Q000494:pharmacology* / Q000627:therapeutic use*; D006525:Hepatitis, Viral, Human / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D006801:Humans; D007378:Interleukins / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism; D008297:Male; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D005466:Fluorocarbons; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; C063334:perftoran